argenx SE raises over $2.5B from share and note offerings
Ticker: ARGX · Form: 6-K · Filed: Jun 17, 2024 · CIK: 1697862
Sentiment: bullish
Topics: financing, equity-offering, debt-offering, capital-raise
TL;DR
argenx just closed a massive $2.5B+ equity and debt offering to fuel pipeline growth.
AI Summary
On June 17, 2024, argenx SE announced the closing of its previously announced offering of 1,725,000 ordinary shares at a price of $315.00 per share, resulting in gross proceeds of approximately $543.4 million. The company also announced the closing of its concurrent offering of 3.45% senior notes due 2031, with aggregate principal amount of $1.0 billion, and the concurrent offering of 4.20% senior notes due 2034, with aggregate principal amount of $1.0 billion. The net proceeds from these offerings are expected to be approximately $2.5 billion.
Why It Matters
This significant capital raise provides argenx with substantial financial resources to advance its pipeline of innovative therapies and potentially fund future growth initiatives.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company's success is still dependent on the clinical development and commercialization of its drug candidates.
Key Numbers
- $543.4M — Ordinary Share Offering Proceeds (Gross proceeds from the sale of 1,725,000 ordinary shares at $315.00 per share.)
- $2.0B — Senior Notes Offering Proceeds (Aggregate principal amount from the concurrent offerings of 3.45% senior notes due 2031 and 4.20% senior notes due 2034.)
- $2.5B+ — Total Net Proceeds (Combined expected net proceeds from the equity and debt offerings.)
Key Players & Entities
- argenx SE (company) — Registrant
- $543.4 million (dollar_amount) — Gross proceeds from ordinary share offering
- $1.0 billion (dollar_amount) — Aggregate principal amount of 3.45% senior notes due 2031
- $1.0 billion (dollar_amount) — Aggregate principal amount of 4.20% senior notes due 2034
- $2.5 billion (dollar_amount) — Expected net proceeds from all offerings
- June 17, 2024 (date) — Date of announcement and closing
FAQ
What was the total amount raised by argenx SE from its recent offerings?
argenx SE raised approximately $543.4 million from its ordinary share offering and $2.0 billion from its senior notes offerings, for a total expected net proceeds of approximately $2.5 billion.
What was the price per share for the ordinary shares offered by argenx SE?
The ordinary shares were offered at a price of $315.00 per share.
What are the maturity dates and interest rates for the senior notes issued by argenx SE?
argenx SE issued $1.0 billion of 3.45% senior notes due 2031 and $1.0 billion of 4.20% senior notes due 2034.
When did argenx SE announce the closing of these offerings?
The company announced the closing of these offerings on June 17, 2024.
What is the primary purpose of the capital raised by argenx SE?
The capital raised is intended to provide argenx with substantial financial resources to advance its pipeline of innovative therapies and potentially fund future growth initiatives.
Filing Stats: 295 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2024-06-17 06:05:43
Filing Documents
- tm2417395d1_6k.htm (6-K) — 12KB
- tm2417395d1_ex99-1.htm (EX-99.1) — 22KB
- tm2417395d1_ex99-1img01.jpg (GRAPHIC) — 9KB
- 0001104659-24-071941.txt ( ) — 48KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: June 17, 2024 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel